During the past decade, Associated Neurologists of Southern Connecticut conducted 22 clinical trials. In the 10-year time frame, 22 clinical trials started and 33 clinical trials were completed, i.e. on average, 150% percent of trials that started reached the finish line to date. In the past 5 years, 3 clinical trials started and 10 clinical trials were completed. i.e. 333.3% of trials that started reached the finish line.

Out of the total clinical trials conducted in "Associated Neurologists of Southern Connecticut" #1 sponsor was "Allergan" with 7 trials, followed by "Pfizer" with 5 trials sponsored, "Ipsen" with 4 trials sponsored, "Eli Lilly and Company" with 3 trials sponsored and "Genentech, Inc." with 3 trials sponsored. Other sponsors include 24 different institutions and companies that sponsored additional 30 trials in total.

In terms of collaborators to trials, out of the total clinical trials conducted in "Associated Neurologists of Southern Connecticut" #1 collaborator was "Pfizer" with 4 trials as a collaborator, "Alzheimer's Association" with 1 trials as a collaborator, "Biogen" with 1 trials as a collaborator, "Mallinckrodt ARD Inc." with 1 trials as a collaborator and "Medelis Inc." with 1 trials as a collaborator. Other collaborators include -3 different institutions and companies that were collaborators in the rest 7 trials.

According to Clinical.Site data, the most researched conditions in "Associated Neurologists of Southern Connecticut" are "Alzheimer's Disease" (6 trials), "Alzheimer Disease" (4 trials), "Cerebral Palsy" (4 trials), "Glioblastoma Multiforme" (4 trials) and "Multiple Sclerosis" (4 trials). Many other conditions were trialed in "Associated Neurologists of Southern Connecticut" in a lesser frequency.

Most popular intervention types in "Associated Neurologists of Southern Connecticut" are "Drug" (41 trials), "Biological" (12 trials), "Device" (4 trials) and "Other" (2 trials). Other intervention types were less common.

The name of intervention was led by "Placebo" (15 trials), "Botulinum toxin type A" (4 trials), "Bapineuzumab 0.5 mg/kg" (3 trials), "Ocrelizumab" (3 trials) and "placebo" (3 trials). Other intervention names were less common.

The vast majority of trials in "Associated Neurologists of Southern Connecticut" are 51 trials for "All" genders.

Currently, there are NaN active trials in "Associated Neurologists of Southern Connecticut". undefined are not yet recruiting, undefined are recruiting, 4 are Active, not recruiting, and undefined are Enrolling by invitation. In total, there were 34 completed trials in Associated Neurologists of Southern Connecticut, 1 suspended trials, and 11 terminated clinical trials to date.

Out of the total trials that were conducted in Associated Neurologists of Southern Connecticut, 2 "Phase 1" clinical trials were conducted, 8 "Phase 2" clinical trials and 35 "Phase 3" clinical trials were conducted as well. "Phase 4" trials included 2 trials, and there were also 3 trials that are defined as “Not Applicable".